Skip to content

Randomized controlled clinical study on the treatment of pediatric herpetic pharyngitis with Xiao'er Fengreqing oral liquid

A randomized controlled multicenter clinical trial on the efficacy and safety of Xiao'er Fengreqing oral liquid combined with Kaihoujian spray in the treatment of children's herpetic angina (wind heat riding spleen syndrome)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000172
Enrollment
Unknown
Registered
2026-01-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpangina

Interventions

Experimental group:Xiaoer Fengreqing Oral Liquid and Kaihoujian Spray (children) were used externally, and the symptomatic treatment was consistent with that of the control group.
Control group:External application and symptomatic treatment of Kaihoujian spray (children type)

Sponsors

Children's Hospital of Chongqing Medical University?
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) Meets the clinical diagnostic criteria for pediatric herpetic pharyngitis in Western medicine; (2) Complies with the traditional Chinese medicine wind heat ride card syndrome differentiation criteria; (3) Disease duration1 year and = 14 years, gender not limited; (7) Agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Children diagnosed with hand, foot, and mouth disease, measles, tonsillitis, chickenpox, herpetic stomatitis, pharyngitis, and other diseases; (2) At the initial diagnosis, the child's condition is severe, with persistent high fever, convulsions, severe mental loss, or neurological involvement such as convulsions and coma, or a history of febrile seizures; (3) Children with comorbidities (such as acute bronchitis, pneumonia, etc.) or existing complications (including but not limited to encephalitis, pulmonary hemorrhage, pulmonary edema, myocardial damage, etc.); (4) Having underlying diseases such as severe respiratory, heart, kidney, liver, blood, endocrine, nervous system, and immunodeficiency diseases; (5) Individuals with glucose-6-phosphate dehydrogenase deficiency (fava bean disease); (6) Individuals who are allergic to known components of the experimental medication; (7) Combine bacterial infections (with white blood cell count>15x10 ^ 9 billion, neutrophil ratio>60%, CRP>20mg, considering possible bacterial infection); (8) Patients who experience diarrhea 48 hours before diagnosis

Design outcomes

Primary

MeasureTime frame
Complete fever time;

Secondary

MeasureTime frame
Effective rate of fever;Disappearance rate of fever;Effective rate of herpes;Disappearance rate of herpes;Disappearance rate of total score of traditional Chinese medicine syndrome;Effective rate of individual symptom;Disappearance rate of individual symptom;Effective rate of sign score;Disappearance rate of sign score;Hand-foot-and-mouth disease conversion rate and, appearance and disappearance time;Effective rate of sore throat;Disappearance rate of sore throat;Effective rate of drooling;Disappearance rate of drooling;Effective rate of coughing;Disappearance rate of coughing;Effective rate of dietary conditions;Disappearance rate of dietary conditions;The onset time of heretic sore throat relief;The disappearance time of heretic sore throat relief;Effective rate of total score of traditional Chinese medicine syndrome;Disappearance rate of total score of traditional Chinese medicine syndrome;

Countries

China

Contacts

Public ContactFu Zhou

?Children's Hospital of Chongqing Medical University?

fu-zhou@126.com023-63622884

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026